Efficacy and safety of shensong yangxin capsules for persistent atrial fibrillation: a Systematic Review and meta-analysis of randomized controlled trials
BackgroundShensong Yangxin (SSYX), a standardized Chinese preparation, is widely utilized in arrhythmia treatment. This research sought to assess the clinical advantages of SSYX for persistent atrial fibrillation (PsAF).MethodsWe searched seven databases and two registries to identify randomized con...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1620340/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849422459795668992 |
|---|---|
| author | Yifan Chen Liuding Wang Yuying Li Runa A Jiahui OuYang Zhonghui Jiang Zhuye Gao Zhuye Gao |
| author_facet | Yifan Chen Liuding Wang Yuying Li Runa A Jiahui OuYang Zhonghui Jiang Zhuye Gao Zhuye Gao |
| author_sort | Yifan Chen |
| collection | DOAJ |
| description | BackgroundShensong Yangxin (SSYX), a standardized Chinese preparation, is widely utilized in arrhythmia treatment. This research sought to assess the clinical advantages of SSYX for persistent atrial fibrillation (PsAF).MethodsWe searched seven databases and two registries to identify randomized controlled trials (RCTs) assessing SSYX as an adjunctive treatment for PsAF. We assessed methodological quality with the Cochrane Risk of Bias Tool 2.0, and conducted meta-analyses with RevMan 5.4.ResultsThe meta-analysis incorporated ten RCTs enrolling 1,713 patients with PsAF. SSYX combined with conventional treatments (CTs) significantly lowered the recurrence of AF compared to CTs alone (risk ratio [RR] = 0.65, 95% conffdence interval [CI] 0.56 to 0.75, P < 0.001). The results also showed that SSYX contributed to the reduction of left atrial diameter (MD = −1.41, 95% CI -2.48 to −0.34, P < 0.001) and P-wave dispersion (MD = −10.37, 95% CI -17.23 to −3.5, P = 0.003). Safety analysis revealed that the combination of SSYX and CTs decreased adverse reaction incidence (RR = 0.54, 95% CI 0.32 to 0.90, P = 0.02). The certainty of evidence was graded as moderate to low.ConclusionSSYX showed potential in preventing AF recurrence in PsAF patients. Nevertheless, these preliminary findings require validation through more rigorously designed trials, given methodological limitations impacting evidence certainty.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251008974, identifier CRD420251008974. |
| format | Article |
| id | doaj-art-c8718a8021f5416aa102cda9d16c6ca8 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-c8718a8021f5416aa102cda9d16c6ca82025-08-20T03:31:06ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-06-011610.3389/fphar.2025.16203401620340Efficacy and safety of shensong yangxin capsules for persistent atrial fibrillation: a Systematic Review and meta-analysis of randomized controlled trialsYifan Chen0Liuding Wang1Yuying Li2Runa A3Jiahui OuYang4Zhonghui Jiang5Zhuye Gao6Zhuye Gao7Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaDepartment of Neurology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaCollege of Basic Medicine, Capital Medical University, Beijing, ChinaDepartment of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaDepartment of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaDepartment of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaDepartment of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaDepartment of Internal Medicine, Yanke Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaBackgroundShensong Yangxin (SSYX), a standardized Chinese preparation, is widely utilized in arrhythmia treatment. This research sought to assess the clinical advantages of SSYX for persistent atrial fibrillation (PsAF).MethodsWe searched seven databases and two registries to identify randomized controlled trials (RCTs) assessing SSYX as an adjunctive treatment for PsAF. We assessed methodological quality with the Cochrane Risk of Bias Tool 2.0, and conducted meta-analyses with RevMan 5.4.ResultsThe meta-analysis incorporated ten RCTs enrolling 1,713 patients with PsAF. SSYX combined with conventional treatments (CTs) significantly lowered the recurrence of AF compared to CTs alone (risk ratio [RR] = 0.65, 95% conffdence interval [CI] 0.56 to 0.75, P < 0.001). The results also showed that SSYX contributed to the reduction of left atrial diameter (MD = −1.41, 95% CI -2.48 to −0.34, P < 0.001) and P-wave dispersion (MD = −10.37, 95% CI -17.23 to −3.5, P = 0.003). Safety analysis revealed that the combination of SSYX and CTs decreased adverse reaction incidence (RR = 0.54, 95% CI 0.32 to 0.90, P = 0.02). The certainty of evidence was graded as moderate to low.ConclusionSSYX showed potential in preventing AF recurrence in PsAF patients. Nevertheless, these preliminary findings require validation through more rigorously designed trials, given methodological limitations impacting evidence certainty.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251008974, identifier CRD420251008974.https://www.frontiersin.org/articles/10.3389/fphar.2025.1620340/fullpersistent atrial fibrillationShensong Yangxin capsulemeta-analysisSystematic reviewtraditional Chinese medicine |
| spellingShingle | Yifan Chen Liuding Wang Yuying Li Runa A Jiahui OuYang Zhonghui Jiang Zhuye Gao Zhuye Gao Efficacy and safety of shensong yangxin capsules for persistent atrial fibrillation: a Systematic Review and meta-analysis of randomized controlled trials Frontiers in Pharmacology persistent atrial fibrillation Shensong Yangxin capsule meta-analysis Systematic review traditional Chinese medicine |
| title | Efficacy and safety of shensong yangxin capsules for persistent atrial fibrillation: a Systematic Review and meta-analysis of randomized controlled trials |
| title_full | Efficacy and safety of shensong yangxin capsules for persistent atrial fibrillation: a Systematic Review and meta-analysis of randomized controlled trials |
| title_fullStr | Efficacy and safety of shensong yangxin capsules for persistent atrial fibrillation: a Systematic Review and meta-analysis of randomized controlled trials |
| title_full_unstemmed | Efficacy and safety of shensong yangxin capsules for persistent atrial fibrillation: a Systematic Review and meta-analysis of randomized controlled trials |
| title_short | Efficacy and safety of shensong yangxin capsules for persistent atrial fibrillation: a Systematic Review and meta-analysis of randomized controlled trials |
| title_sort | efficacy and safety of shensong yangxin capsules for persistent atrial fibrillation a systematic review and meta analysis of randomized controlled trials |
| topic | persistent atrial fibrillation Shensong Yangxin capsule meta-analysis Systematic review traditional Chinese medicine |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1620340/full |
| work_keys_str_mv | AT yifanchen efficacyandsafetyofshensongyangxincapsulesforpersistentatrialfibrillationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT liudingwang efficacyandsafetyofshensongyangxincapsulesforpersistentatrialfibrillationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yuyingli efficacyandsafetyofshensongyangxincapsulesforpersistentatrialfibrillationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT runaa efficacyandsafetyofshensongyangxincapsulesforpersistentatrialfibrillationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT jiahuiouyang efficacyandsafetyofshensongyangxincapsulesforpersistentatrialfibrillationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT zhonghuijiang efficacyandsafetyofshensongyangxincapsulesforpersistentatrialfibrillationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT zhuyegao efficacyandsafetyofshensongyangxincapsulesforpersistentatrialfibrillationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT zhuyegao efficacyandsafetyofshensongyangxincapsulesforpersistentatrialfibrillationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |